Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

LUX-Breast 1; An Open Label, Randomised Phase III Trial of BIBW 2992 and Vinorelbine Versus Trastuzumab and Vinorelbine in Patients With Metastatic HER2-overexpressing Breast Cancer Failing One Prior Trastuzumab Treatment

NCT01125566 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

NCT NCT01125566
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01125566 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
LUX-Breast 1; An Open Label, Randomised Phase III Trial of BIBW 2992 and Vinorelbine Versus Trastuzumab and Vinorelbine in Patients With Metastatic HER2-overexpressing Breast Cancer Failing One Prior Trastuzumab Treatment
Lead sponsor
Boehringer Ingelheim
Phase
Phase 3
Overall status
Completed
Start date
June 22, 2010
Completion date
July 6, 2018
Enrollment
508 (actual)
Sites
207

Conditions

As the registry lists them; a condition with its own page is linked.

breast neoplasms